艾昆纬-个性化医疗时代的肿瘤治疗可及性（英）

AUGUST2 0 2 5Trends in Regulatory Approval and Reimbursement for Select Countries in the Middle East and AfricaOncology Therapy Access in the Era of Personalized MedicineResearch by the IQVIA Institute in 2024 revealed geographical differences in the availability of oncology novel active substances (NAS) across select EU countries, Australia, Canada, and Brazil, influenced by factors such as country-level variations in clinical data acceptance, health technology assessment (HTA) processes, clinical endpoint priorities, and manufacturer strategies.Building on these insights, trends in overall regulatory approvals and reimbursement have been analyzed for oncology therapies indicated in solid tumors and hematological malignancies in two Gulf Cooperation Council (GCC) nations — Saudi Arabia and United Arab Emirates (UAE) and three African countries — Algeria, Egypt, and South Africa. Important dynamics associated with the oncology therapy landscape such as the registration and reimbursement of selected innovative targeted therapies including antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs), cell and gene therapies (CAGTs), and immuno-oncology checkpoint inhibitors have been assessed. The associated companion diagnostic requirements to administer some of these therapies are also discussed.This report outlines the underlying factors contributing to the oncology therapy access challenges, examines their implications, and highlights ongoing country level efforts to address them. It concludes with action items aimed at improving oncology therapy access. The findings are intended to support discussions on existing hurdles, showcase on-going initiatives, and guide strategies to enhance access to precision oncology therapies.This report has been developed independently by the IQVIA Institute for Human Data Science based on research and analysis undertaken by the IQVIA Middle East and Africa Strategy Consulting Service. Funding for this work and report has been provided by AbbVie. The contributions to this report of Aanchal Aanchal, Sangeeth Suresh, and others at IQVIA are gratefully acknowledged. Find Out MoreIf you wish to receive future reports from the IQVIA Institute for Human Data Science or join our mailing list, visit iqviainstitute.org. MURRAY AITKENExecutive Director IQVIA Institute for Human Data ScienceIntroduction©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA and the IQVIA Institute.Oncology Therapy Access in the Era of Personalized Medicine: Select Countries in the Middle East and AfricaREFERENCING THIS REPORTPlease use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Oncology Therapy